MiNA Therapeutics Ltd, which is developing drugs based on small activating RNA molecules, has raised £23 million in a Series A financing round to advance the clinical development of its lead product as a combination treatment for cancer. The financing was led by the Israeli venture capital fund aMoon, with participation from existing investors.
